NCT-501 is primarily used in research settings as a selective inhibitor of the enzyme soluble epoxide hydrolase (sEH). By inhibiting sEH, it helps stabilize endogenous epoxy fatty acids, which have anti-inflammatory, analgesic, and vasodilatory effects. This makes NCT-501 a valuable tool in studying inflammatory pain, neuropathic pain, and cardiovascular conditions such as hypertension and vascular inflammation. It has shown efficacy in preclinical models for reducing pain sensitivity without central nervous system side effects, suggesting potential for development in non-opioid pain therapies. Additionally, its role in modulating lipid signaling pathways supports its investigation in metabolic and renal diseases.